Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LGVN

Longeveron Inc

Dec 12 • 04:00PM ET

1.86

Dollar change -0.10
Percentage change -5.10	%

Healthcare • Biotechnology • USA • NASD

Peers: ADMA CAPR SVRA APRE CVM HOOK JAGX HURA MTNB

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.33	Insider Own	27.90%	Shs Outstand	13.35M	Perf Week	-1.06%
Market Cap	27.60M	Forward P/E	-	EPS next Y	-1.49	Insider Trans	-0.03%	Shs Float	4.58M	Perf Month	-19.13%
Income	-26.57M	PEG	-	EPS next Q	-0.37	Inst Own	14.81%	Short Float	21.59%	Perf Quarter	-10.58%
Sales	1.85M	P/S	14.92	EPS this Y	65.93%	Inst Trans	166.97%	Short Ratio	1.99	Perf Half Y	-30.86%
Book/sh	1.73	P/B	1.08	EPS next Y	57.27%	ROA	-86.07%	Short Interest	0.99M	Perf Year	-90.84%
Cash/sh	1.54	P/C	1.21	EPS next 5Y	-	ROE	-110.75%	52W Range	0.77 - 22.20	Perf YTD	-86.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.24%	ROI	-99.84%	52W High	-91.62%	Beta	0.30
Dividend TTM	-	Quick Ratio	7.67	Sales past 5Y	7.76%	Gross Margin	21.65%	52W Low	141.34%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	7.67	EPS Y/Y TTM	35.30%	Oper. Margin	-954.59%	RSI (14)	41.12	Volatility	7.70% 7.57%
Employees	25	Debt/Eq	0.06	Sales Y/Y TTM	141.46%	Profit Margin	-1434.56%	Recom	1.00	Target Price	8.67
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	87.98%	Payout	-	Rel Volume	0.53	Prev Close	1.96
Sales Surprise	95.45%	EPS Surprise	12.82%	Sales Q/Q	415.33%	Earnings	Nov 12 AMC	Avg Volume	496.36K	Price	1.86
SMA20	-5.58%	SMA50	-8.13%	SMA200	-21.39%	Trades		Volume	260,799	Change	-5.10%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$10

Dec-07-24 05:20AM	Longeveron initiated with a Buy at Roth MKM (TipRanks)
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 09:05AM	Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Longeveron Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.99% -7.83%
09:05AM	Loading…
Nov-11-24 09:05AM	Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) (GlobeNewswire)
Nov-04-24 04:05PM	Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (GlobeNewswire) +6.40%
Oct-29-24 10:00AM	Longeveron Presents Lomecel-B Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) (GlobeNewswire)
Oct-27-24 03:10PM	Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting (GlobeNewswire)
Oct-14-24 09:05AM	Longeveron Lomecel-B Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) (GlobeNewswire) +8.38%
Oct-09-24 09:05AM	Longeveron Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting (GlobeNewswire)
Oct-07-24 09:05AM	Longeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day (GlobeNewswire)
Oct-02-24 09:05AM	Longeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 09:05AM	Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-03-24 09:00AM	Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) (GlobeNewswire)
04:05PM	Loading…
Aug-26-24 04:05PM	Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.23% -5.39%
Aug-14-24 04:05PM	Longeveron Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.75%
Aug-05-24 04:05PM	Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -8.30% +9.06%
Jul-28-24 04:51PM	Longeveron Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B in Mild Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) (GlobeNewswire)
Jul-19-24 04:05PM	Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-18-24 08:45AM	Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.67%
Jul-17-24 08:00AM	Longeveron Announces U.S. FDA Grants Fast Track Designation for Lomecel-B for the Treatment of Mild Alzheimer's Disease (GlobeNewswire) +10.80%
Jul-10-24 12:08PM	PLUG Stock: Plug Power Shares Hydrogen Refueling Station Update (InvestorPlace) +58.54%
11:34AM	Why Is Longeveron (LGVN) Stock Up 53% Today? (InvestorPlace)
07:30AM	Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease (GlobeNewswire)
Jul-09-24 09:00AM	Neha Motwani Elected to Longeveron Board of Directors (GlobeNewswire) +38.65%
Jul-08-24 09:00AM	Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron Board of Directors (GlobeNewswire) +19.65%
Jun-21-24 08:35AM	Life Science Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) -10.20%
Jun-19-24 10:30AM	3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028 (InvestorPlace)
Jun-18-24 04:48PM	Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction (GlobeNewswire) -7.50% +10.36%
08:35AM	Loading…
08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for June 20th (GlobeNewswire)
Jun-17-24 09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire) -24.76%
09:00AM	Longeveron to Present at the Virtual Life Sciences Investor Forum on June 20, 2024 (GlobeNewswire)
08:38AM	Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire) +120.73%
Jun-11-24 09:00AM	Longeveron Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease (GlobeNewswire) -22.64%
07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 09:00AM	Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024 (GlobeNewswire)
Jun-03-24 09:00AM	Longeveron Announces Contract Development and Manufacturing Business and First Contract (GlobeNewswire) -5.45%
May-28-24 08:05AM	Longeveron to Attend BIO International Convention 2024 (GlobeNewswire)
May-14-24 04:05PM	Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +6.92%
May-10-24 04:05PM	Longeveron Announces Board of Directors Planned Transitions (GlobeNewswire) -5.52% -10.65%
May-02-24 08:03AM	Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 04:05PM	Longeveron to Present at the Planet MicroCap Showcase (GlobeNewswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 04:05PM	Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering (GlobeNewswire)
Apr-17-24 08:00AM	Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds (GlobeNewswire) -40.79%
Apr-16-24 01:08PM	Hedge Fund and Insider Trading News: Ken Griffin, Per Johansson, David Tepper, Michael Platt, Third Point LLC, Millennium Management, Bridgewater Associates, Paloma Partners, Longeveron Inc (LGVN), MongoDB, Inc. (MDB) and More (Insider Monkey) +20.48%
Apr-15-24 08:30AM	Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) (GlobeNewswire) +73.37%
08:24AM	Why Is Longeveron (LGVN) Stock Up 48% Today? (InvestorPlace)
Apr-11-24 05:17PM	Longeveron Announces Closing of $5.2 Million Public Offering (GlobeNewswire) -10.22% -16.34%
Apr-08-24 02:15PM	Longeveron Announces Pricing of $5.25 Million Public Offering (GlobeNewswire)
08:30AM	Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals (GlobeNewswire)
07:56AM	Why Is Longeveron (LGVN) Stock Up 82% Today? (InvestorPlace)
Mar-19-24 04:01PM	Longeveron Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -19.97%
Feb-28-24 10:05AM	With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus (FierceBiotech.com) -5.95%
09:19AM	Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:05PM	Longeveron Reports Year-End 2023 Results and Provides Corporate Update (GlobeNewswire) +7.19%
Feb-21-24 04:05PM	Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024 (GlobeNewswire)
Jan-29-24 08:00AM	Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B (GlobeNewswire) -16.07%
Dec-22-23 04:05PM	Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +7.20% +8.96%
Dec-21-23 10:34AM	UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.84%
08:00AM	Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-20-23 08:00AM	Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.92%
Nov-14-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa'el Hashad, CEO of Longeveron Inc. (GlobeNewswire)
Nov-11-23 09:00AM	Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
08:38AM	Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:30AM	Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire) -5.70%
Nov-03-23 08:00AM	Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 (GlobeNewswire)
Oct-24-23 08:30AM	Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B for the Treatment of Mild Alzheimer's (GlobeNewswire)
Oct-13-23 04:05PM	Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +7.43%
Oct-12-23 08:00AM	Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.24%
Oct-05-23 07:00AM	Longeveron Announces Positive Top-Line Results for Lomecel-B in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.73%
Sep-12-23 09:00AM	Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market (News Direct)
Sep-11-23 08:00AM	Longeveron Issues Letter to Stockholders (GlobeNewswire)
Sep-07-23 08:30AM	IBN Coverage Initiated for Longeveron Inc. (GlobeNewswire)
08:00AM	Long-term Survival Data from Longeverons ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
Sep-05-23 08:00AM	Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire)
Aug-29-23 08:00AM	Longeveron to Participate in the 149th Annual National Investment Banking Association Conference (GlobeNewswire)
Aug-22-23 08:00AM	Longeveron Rights Offering Subscription Period Begins (GlobeNewswire) +8.20%
Aug-16-23 09:13AM	Longeveron Rights Offering Declared Effective and Calendar Finalized (GlobeNewswire)
Aug-14-23 04:05PM	Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B on August 16, 2023 (GlobeNewswire) -7.03%
08:00AM	Longeveron Announces Pricing for Rights Offering and Expected Calendar (GlobeNewswire)
Aug-11-23 07:30AM	Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
07:24AM	LGVN Makes Progress in Treatment for Devastating Diseases (Zacks Small Cap Research)
07:00AM	Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B in Hypoplastic Left Heart Syndrome (GlobeNewswire)
Aug-08-23 09:25AM	Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions (News Direct)
07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Aug-07-23 08:00AM	Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Longeveron Appoints Lisa Locklear as Chief Financial Officer (GlobeNewswire)
Jul-11-23 08:00AM	Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer (GlobeNewswire)
Jul-10-23 08:00AM	Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors (GlobeNewswire)
Jul-07-23 09:00AM	HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate Could Longeverons Lomecel-B Improve Outcomes? (News Direct)
Jul-06-23 11:12AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.) -5.66%
Jun-27-23 06:07PM	Longeveron Files Registration Statement for Rights Offering (GlobeNewswire) -5.85%
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire)
May-12-23 08:32AM	LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates (InvestorPlace)
08:20AM	LGVN: Announces Results and Progress on a Devastating Disease (Zacks Small Cap Research)

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baluch Khoso	Director	Dec 02 '24	Sale	2.07	1,250	2,588	23,750	Dec 04 06:00 PM
Baluch Khoso	Director	Nov 27 '24	Proposed Sale	2.06	1,250	2,575		Nov 27 04:43 PM
Hare Joshua	Chief Scientific Officer	Apr 10 '24	Buy	2.35	106,383	250,000	590,727	Apr 12 07:00 PM
Hare Joshua	Chief Scientific Officer	Apr 11 '24	Buy	2.35	42,553	100,000	633,280	Apr 12 07:00 PM
Hashad Mohamed Wa'el Ahmed	Chief Executive Officer	Apr 11 '24	Buy	2.35	10,638	24,999	19,616	Apr 12 07:00 PM
Soffer Rock	Director	Apr 10 '24	Buy	2.35	106,383	250,000	176,619	Apr 12 07:00 PM
Soffer Rock	Director	Apr 11 '24	Buy	2.35	31,915	75,000	208,534	Apr 12 07:00 PM
Ross Cathy	Director	Jan 10 '24	Buy	1.31	5,000	6,544	10,000	Jan 11 06:00 PM
Baluch Khoso	Director	Dec 29 '23	Buy	1.43	8,322	11,915	15,000	Jan 02 06:00 PM
Baluch Khoso	Director	Dec 28 '23	Buy	1.40	1,678	2,342	6,678	Jan 02 06:00 PM
PFEFFER JEFFREY	Director	Dec 28 '23	Buy	1.35	10,000	13,500	15,000	Dec 29 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGVN

Longeveron Inc

Upgrade your FINVIZ experience